Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SELTS:0RAR -0.65%71 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates LTS:0RAR with a GF Score™ of 71/100 and a GF Value™ of €27.96 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Stratec SE ranks worse than 71.31% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Stratec SE's Debt-to-Equity or its related term are showing as below:
LTS:0RAR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.4 Med: 0.5 Max: 0.64
Current: 0.55
During the past 13 years, the highest Debt-to-Equity Ratio of Stratec SE was 0.64. The lowest was 0.40. And the median was 0.50.
LTS:0RAR's Debt-to-Equity is ranked worse than 71.31% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs LTS:0RAR: 0.55
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Stratec SE Debt-to-Equity Related Terms
Stratec SE Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Stratec SE's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAR vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Stratec SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Stratec SE's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (LTS:0RAR) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Stratec SE and its competitors. Over the past decade, Stratec SE's Debt-to-Equity has ranged from 0.40 to 0.64. According to the industry distribution chart, Stratec SE ranks #497 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Stratec SE's Debt-to-Equity too high?
Stratec SE's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 0.64. Based on the distribution chart, Stratec SE ranks #497 out of 697 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stratec SE has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #497 out of 697 companies for Debt-to-Equity. This places Stratec SE in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Historically, Stratec SE's own Debt-to-Equity has ranged from 0.40 to 0.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (LTS:0RAR) is currently considered Modestly Undervalued. The stock's GF Value™ is €27.96, compared to a current price of €22.90 — trading 18.1% below its estimated fair value. The current Debt-to-Equity is 0.00. Stratec SE's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Stratec SE (LTS:0RAR), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (LTS:0RAR) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €22.90 is trading 18.1% below its estimated GF Value™ of €27.96.
GuruFocus considers Stratec SE to be Modestly Undervalued.
Key valuation signals for LTS:0RAR:
Debt-to-Equity: 0.00
GF Value™: €27.96 vs. price of €22.90 (18.1% below fair value)
No single metric tells the full story. See the LTS:0RAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
71GF Score
Get the complete analysis for LTS:0RAR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAR has been successfully added to your 
